Evidence map›Paper›PMID 34639014›Full record

ReviewInternational journal of molecular sciences2021

Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?

Ornella Franzese, Francesco Torino, Elisa Giannetti, Giorgia Cioccoloni, Angelo Aquino, Isabella Faraoni, Maria Pia Fuggetta, Liana De Vecchis, Anna Giuliani, Bernd Kaina and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Tumor neoantigens and tumor immunotherapies.Aging medicine (Milton (N.S.W)) · 2024
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Ornella FranzeseSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Francesco TorinoDepartment of Systems Medicine, Medical Oncology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-5828-4438
Elisa GiannettiDepartment of Systems Medicine, Medical Oncology, University of Rome Tor Vergata, 00133 Rome, Italy.
Giorgia CioccoloniSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Angelo AquinoSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Isabella FaraoniSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-0100-6247
Maria Pia FuggettaInstitute of Translational Pharmacology, Consiglio Nazionale delle Ricerche (CNR), Via Fosso del Cavaliere, 00133 Rome, Italy.
Liana De VecchisSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Anna GiulianiInstitute of Translational Pharmacology, Consiglio Nazionale delle Ricerche (CNR), Via Fosso del Cavaliere, 00133 Rome, Italy.
Bernd KainaInstitute of Toxicology, University Medical Center, D-55131 Mainz, Germany.ORCID 0000-0002-8217-0809
Enzo BonmassarSchool of Medicine, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
University of Rome Tor Vergata · ITIstituto di Farmacologia Traslazionale · ITJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current state of cancer treatment is still far from being satisfactory considering the strong impairment of patients' quality of life and the high lethality of malignant diseases. Therefore, it is critical for innovative approaches to be tested in the near future. In view of the crucial role that is played by tumor immunity, the present review provides essential information on the immune-mediated effects potentially generated by the interplay between ionizing radiation and cytotoxic antitumor agents when interacting with target malignant cells. Therefore, the radiation-dependent abscopal effect (i.e., a biological effect of ionizing radiation that occurs outside the irradiated field), the influence of cancer chemotherapy on the antigenic pattern of target neoplastic cells, and the immunogenic cell death (ICD) caused by anticancer agents are the main topics of this presentation. It is widely accepted that tumor immunity plays a fundamental role in generating an abscopal effect and that anticancer drugs can profoundly influence not only the host immune responses, but also the immunogenic pattern of malignant cells. Remarkably, several anticancer drugs impact both the abscopal effect and ICD. In addition, certain classes of anticancer agents are able to amplify already expressed tumor-associated antigens (TAA). More importantly, other drugs, especially triazenes, induce the appearance of new tumor neoantigens (TNA), a phenomenon that we termed drug-induced xenogenization (DIX). The adoption of the abscopal effect is proposed as a potential therapeutic modality when properly applied concomitantly with drug-induced increase in tumor cell immunogenicity and ICD. Although little to no preclinical or clinical studies are presently available on this subject, we discuss this issue in terms of potential mechanisms and therapeutic benefits. Upcoming investigations are aimed at evaluating how chemical anticancer drugs, radiation, and immunotherapies are interacting and cooperate in evoking the abscopal effect, tumor xenogenization and ICD, paving the way for new and possibly successful approaches in cancer therapy.

Indexed as

Radiation, IonizingAnimalsAntineoplastic AgentsBiomarkersDisease ManagementDisease SusceptibilityDrug-Related Side Effects and Adverse ReactionsHumansImmunityModels, AnimalNeoplasmsRadiation InjuriesRadiotherapyAntineoplastic AgentsBiomarkersabscopal effectalkylating agentsdacarbazineimmune checkpointsimmune responsetemozolomidetumor neoantigensxenogenization

Identifiers

PMID34639014
PMCPMC8509363
OpenAlexW3203159104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.